Research progress of stereotactic body radiation therapy for lung oligometastases of colorectal cancer

doi:10.3760/cma.j.cn371439-20200306-00092

Abstract

Abstract:

Compared with surgery and radiofrequency ablation, stereotactic body radiation therapy (SBRT) has similar efficacy for local treatment of colorectal cancer with pulmonary oligometastasis, but it applies to a wide range of people. Oligometastasis of colorectal cancer may have radiation resistance, and good local control can be achieved by increasing the dose. The prescription dose and prognostic factors of SBRT in the treatment of lung oligometastasis of colorectal cancer have not been determined. There are no serious toxicities in most studies, but there are still radiation-related adverse events.

Key words: Colorectal neoplasms, Neoplasm metastasis, Lung neoplasms, Stereotactic body radiation therapy

Zhang Lili, Yu Yonghua. Research progress of stereotactic body radiation therapy for lung oligometastases of colorectal cancer[J]. Journal of International Oncology, 2020, 47(10): 630-633.

References 31

[1]	Li S, Dong D, Geng J, et al. Prognostic factors and optimal response interval for stereotactic body radiotherapy in patients with lung oligometastases or oligoprogression from colorectal cancer[J]. Front Oncol, 2019,9:1080. DOI: 10.3389/fonc.2019.01080. doi: 10.3389/fonc.2019.01080 pmid: 31681609
[2]	Cheung FP, Alam NZ, Wright GM. The past, present and future of pulmonary metastasectomy: a review article[J]. Ann Thorac Cardiovasc Surg, 2019,25(3):129-141. DOI: 10.5761/atcs.ra.18-00229. doi: 10.5761/atcs.ra.18-00229 pmid: 30971647
[3]	中国医师协会外科医师分会多学科综合治疗专业委员会, 中国抗癌协会大肠癌专业委员会. 结直肠癌肺转移多学科综合治疗专家共识(2018版)[J]. 实用肿瘤杂志, 2018,33(6):487-501. DOI: 10.13267/j.cnki.Syzlzz.2018.06.001.
[4]	Sharma A, Baker S, Duijm M, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy[J]. Radiother Oncol, 2020,144:23-29. DOI: 10.1016/j.radonc.2019.10.004. doi: 10.1016/j.radonc.2019.10.004 pmid: 31710940
[5]	Onderdonk BE, Gutiontov SI, Chmura SJ. The evolution (and future) of stereotactic body radiotherapy in the treatment of oligometastatic disease[J]. Hematol Oncol Clin North Am, 2020,34(1):307-320. DOI: 10.1016/ j.hoc.2019.09.003. pmid: 31739951
[6]	Jung J, Song SY, Kim JH, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer[J]. Radiat Oncol, 2015,10:238. DOI: 10.1186/s13014-015-0546-x. doi: 10.1186/s13014-015-0546-x pmid: 26588896
[7]	Dell'Acqua V, Surgo A, Kraja F, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions[J]. Clin Exp Metastasis, 2019,36(4):331-342. DOI: 10.1007/s10585-019-09976-z.
[8]	Treasure T, Farewell V, Macbeth F, et al. Pulmonary metastasectomy versus continued active monitoring in colorectal cancer (PulMiCC): a multicentre randomised clinical trial[J]. Trials, 2019,20(1):718. DOI: 11186/s13063-019-3837-y.
[9]	Olson R, Senan S, Harrow S, et al. Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial[J]. Int J Radiat Oncol Biol Phys, 2019,105(5):943-947. DOI: 10. 1016/j.ijrobp.2019.08.041.
[10]	Lyons NJ, Pathak S, Daniels IR, et al. Percutaneous management of pulmonary metastases arising from colorectal cancer; a systematic review[J]. Eur J Surg Oncol, 2015,41(11):1447-1455. DOI: 10.1016/j.ejso.2015.07.018.
[11]	Hasegawa T, Takaki H, Kodama H, et al. Three-year survival rate after radiofrequency ablation for surgically resectable colorectal lung metastases: a prospective multicenter study[J]. Radiology, 2020,294(3):686-695. DOI: 10. 1148/radiol.2020191272. pmid: 31934829
[12]	de Baère T, Aupérin A, Deschamps F, et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases[J]. Ann Oncol, 2015,26(5):987-991. DOI: 10.1093/annonc/mdV037. doi: 10.1093/annonc/mdv037 pmid: 25688058
[13]	Gemmete JJ. Percutaneous radiofrequency ablation is ready for prime time in the treatment of colorectal pulmonary metastases[J]. Radio-logy, 2020,294(3):696-697. DOI: 10.1148/radiol.2020-192558.
[14]	Bernstein MB, Krishnan S, Hodge JW, et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?[J]. Nat Rev Clin Oncol, 2016,13(8):516-524. DOI: 10.1038/nrclinonc.2016.30. pmid: 26951040
[15]	Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: phase Ⅰ results and immunologic correlates from peripheral T cells[J]. Clin Cancer Res, 2017,23(6):1388-1396. DOI: 10.1158/1078-0432.CCR-16-1432. doi: 10.1158/1078-0432.CCR-16-1432 pmid: 27649551
[16]	Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors[J]. J Clin Oncol, 2018,36(16):1611-1618. DOI: 10.1200/JCO.2017.76.2229. doi: 10.1200/JCO.2017.76.2229 pmid: 29437535
[17]	Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial[J]. Lancet, 2019,393(10185):2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. pmid: 30982687
[18]	Filippi AR, Badellino S, Ceccarelli M, et al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study[J]. Int J Radiat Oncol Biol Phys, 2015,91(3):524-529. DOI: 10.1016/j.ijrobp.2014.10.046. doi: 10.1016/j.ijrobp.2014.10.046 pmid: 25542308
[19]	Agolli L, Bracci S, Nicosia L, et al. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients : outcomes and prognostic factors after long-term follow-up[J]. Clin Colorectal Cancer, 2017,16(1):58-64. DOI: 10.1016/j.clcc.2016.07.004. doi: 10.1016/j.clcc.2016.07.004 pmid: 27522627
[20]	Comito T, Cozzi L, Clerici E, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach[J]. BMC Cancer, 2014,14:619. DOI: 10.1186/1471-2407-14-619.
[21]	Helou J, Thibault I, Poon I, et al. Stereotactic ablative radiation therapy for pulmonary metastases: histology, dose, and indication matter[J]. Int J Radiat Oncol Biol Phys, 2017,98(2):419-427. DOI: 10.1016/j.ijrobp.2017.02.093. doi: 10.1016/j.ijrobp.2017.02.093 pmid: 28463162
[22]	Jingu K, Matsushita H, Yamamoto T, et al. Stereotactic radiothe-rapy for pulmonary oligometastases from colorectal cancer: a systematic review meta-analysis[J]. Technol Cancer Res Treat, 2018,17:1533033818794936. DOI: 10.1177/1533033818794936. pmid: 30145943
[23]	Klement RJ, Abbasi-Senger N, Adebahr S, et al. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases[J]. BMC Cancer, 2019,19(1):173. DOI: 10.1186/s12885-019-53. doi: 10.1186/s12885-019-5362-5
[24]	Guckenberger M, Klement RJ, Allgäuer M, et al. Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy[J]. Radiother Oncol, 2016,118(3):485-491. DOI: 10.1016/j.radonc.2015.09.008. doi: 10.1016/j.radonc.2015.09.008 pmid: 26385265
[25]	Ricco A, Davis J, Rate W, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch^® patient Registry's experience[J]. Radiat Oncol, 2017,12(1):35. DOI: 10.1186/s13014-017-0773-4. doi: 10.1186/s13014-017-0773-4
[26]	Jingu K, Matsuo Y, Onishi H, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer[J]. Anticancer Res, 2017,37(5):2709-2713. DOI: 10.21873/anticanres.11621. doi: 10.21873/anticanres.11621 pmid: 28476849
[27]	Qiu H, Katz AW, Chowdhry AK, et al. Stereotactic body radiothe-rapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival[J]. Am J Clin Oncol, 2018,41(1):53-58. DOI: 10.1097/COC.0000000000000220. doi: 10.1097/COC.0000000000000220 pmid: 26270442
[28]	Pasalic D, Lu Y, Betancourt-Cuellar SL, et al. Stereotactic ablative radiation therapy for pulmonary metastases: improving overall survi-val and identifying subgroups at high risk of local failure[J]. Radiother Oncol, 2020,145:178-185. DOI: 10.1016/j.radonc.2020.01.010. doi: 10.1016/j.radonc.2020.01.010 pmid: 32044530
[29]	Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review[J]. J Thorac Oncol, 2010,5(7):1091-1099. DOI: 10.1097/JTO.0b013e3181de-7143. doi: 10.1097/JTO.0b013e3181de7143 pmid: 20479693
[30]	Zhao J, Yorke ED, Li L, et al. Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies[J]. Int J Radiat Oncol Biol Phys, 2016,95(5):1357-1366. DOI: 10.1016/j.ijrobp.2016.03.024. doi: 10.1016/j.ijrobp.2016.03.024 pmid: 27325482
[31]	Yamashita H, Takahashi W, Haga A, et al. Radiation pneumonitis after stereotactic radiation therapy for lung cancer[J]. World J Radiol, 2014,6(9):708-715. DOI: 10.4329/wjr.v6.i9.708. doi: 10.4329/wjr.v6.i9.708 pmid: 25276313